Efficacy and Safety of Tacrolimus Therapy for Severe and Steroid-refractory Ulcerative Colitis: A Systematic Review and Meta-analysis

2015 ◽  
Vol 110 ◽  
pp. S828-S829
Author(s):  
Yuga Komaki ◽  
Fukiko Komaki ◽  
Atsushi Sakuraba
2021 ◽  
Author(s):  
Quanhui Zhang ◽  
Yongwen Deng ◽  
Jinlong Wang ◽  
Feihong Huang ◽  
Yiduo Zhou ◽  
...  

2018 ◽  
Vol 21 ◽  
pp. S82
Author(s):  
R Thode ◽  
P Veeranki ◽  
A Inuganti ◽  
G Paladugu ◽  
RK Hyderboini ◽  
...  

2019 ◽  
Vol 26 (1) ◽  
pp. 24-32 ◽  
Author(s):  
Biyu Wu ◽  
Jinglu Tong ◽  
Zhihua Ran

AbstractInflammatory bowel diseases are known for a chronic inflammatory process of the gastrointestinal tract and include Crohn’s disease and ulcerative colitis (UC). Patients who are dependent on or resistant to corticosteroids account for about 20% of severe UC patients. Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. Tacrolimus has been demonstrated to have remarkable therapeutic efficacy in UC patients, without increased risk of severe adverse effects such as induction of remission and maintenance therapy. This article reviews the mechanism of action, pharmacogenetics, efficacy, and safety of tacrolimus for patients with steroid-refractory ulcerative colitis.


Sign in / Sign up

Export Citation Format

Share Document